Pharma Pulse 9/12/24: Enhancing Biologics Development, Study Finds Cap on Out-of-Pocket Costs Saves Cancer Patients $7,000 & more

Regulatory CMC: Enhancing Biologics Development
Preventing delays and accelerating the progression of these critical therapies.

Study Finds Cap on Out-of-Pocket Costs Saves Cancer Patients $7,000

The Inflation Reduction Act’s limit on Medicare Part D spending can lead to savings for patients prescribed oral chemotherapy drugs.

AI Will Force a Transformation of Tech Infrastructure

Corporate technology executives need to ensure their cloud and private infrastructure is ready to handle their data needs to come.

FDA Grants Clearance for Immunis’ Phase II Sarcopenic Obesity Trial

Immunis, Inc. was recently granted permission by the FDA to proceed with its Phase II clinical trial testing its investigational secretome (IMMUNA) in reversing sarcopenic obesity. The news comes shortly after Immunis completed secretome-treatment of its third patient cohort in a Phase I/IIa clinical trial for age-related muscle atrophy (sarcopenia).

ACTO on LinkedIn

While this Pharmaceutical Executive article deals with #AI in #DrugDiscovery, what caught our attention was the subhead -- "AI is a tool to make drug discovery cheaper, faster, and better — not a replacement for human ingenuity."

This idea is just as applicable to helping field reps stay competent and confident, and maintain their authority and impact with #HCPs.

https://lnkd.in/gZ2RKBrD

#IntelligentFieldExcellence #SalesCoaching #BiopharmaSales

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs